Herman Sari M, Vender Ronald B
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
J Cutan Med Surg. 2003 Nov-Dec;7(6):467-73. doi: 10.1007/s10227-003-0164-3.
Atopic dermatitis (AD) is an inflammatory skin disorder that is exceedingly challenging to treat. A prominent feature of AD is chronic pruritus. Early evidence suggested that pruritus in AD was partially due to mast cell release of histamines. Conversely, recent studies do not validate the role of histamine in the pathogenesis of pruritus. Conventional management continues to include the wide use of antihistamines to treat the persistent itch, however, there is an urgent need for therapy which will reduce the severity of pruritus for these patients.
To review the evidence in the literature for the use of antihistamines in the treatment of atopic dermatitis.
A MEDLINE search (1966-2002) was performed to obtain studies examining the use of antihistamines in the treatment of atopic dermatitis. Search terms included: atopic dermatitis; eczema; antihistamines; azatadine; brompheniramine; cetirizine; chlorpheniramine; clemastine; cyclizine; cyproheptadine; desloratadine; diphenhydramine; fexofenadine; hydroxyzine; loratadine; meclizine; promethazine; trimeprazine. Further references were gathered from these publications.
Historically, antihistamines have been used in the treatment of AD. However, this review shows that the evidence for its use is inconclusive. At present, several antihistamines continue to provide relief of pruritus by central sedation, and they can also be used therapeutically for concomitant allergic conditions associated with AD. More clinical trials examining the therapeutic efficacy of antihistamines, especially with the newer nonsedating antihistamines, are necessary to elucidate their role in the treatment of AD.
Dermatologists require additional evidence regarding the efficacy of antihistamines and their mechanism of action in the treatment of AD to enhance patient care.
特应性皮炎(AD)是一种炎症性皮肤病,治疗极具挑战性。AD的一个突出特征是慢性瘙痒。早期证据表明,AD中的瘙痒部分归因于肥大细胞释放组胺。相反,近期研究并未证实组胺在瘙痒发病机制中的作用。传统治疗仍广泛使用抗组胺药来治疗持续性瘙痒,然而,迫切需要一种能减轻这些患者瘙痒严重程度的疗法。
综述文献中关于抗组胺药治疗特应性皮炎的证据。
进行了一项MEDLINE检索(1966 - 2002年),以获取研究抗组胺药治疗特应性皮炎的研究。检索词包括:特应性皮炎;湿疹;抗组胺药;阿扎他定;溴苯那敏;西替利嗪;氯苯那敏;氯马斯汀;赛克利嗪;赛庚啶;地氯雷他定;苯海拉明;非索非那定;羟嗪;氯雷他定;美克洛嗪;异丙嗪;曲美苄嗪。从这些出版物中收集了更多参考文献。
从历史上看,抗组胺药一直用于治疗AD。然而,本综述表明其使用证据尚无定论。目前,几种抗组胺药继续通过中枢镇静来缓解瘙痒,它们还可用于治疗与AD相关的伴随过敏性疾病。需要更多临床试验来研究抗组胺药,尤其是新型非镇静性抗组胺药的治疗效果,以阐明它们在AD治疗中的作用。
皮肤科医生需要更多关于抗组胺药在AD治疗中的疗效及其作用机制的证据,以改善患者护理。